(Q40639122)

22 September 2017

title

Rapid assessment of P-glycoprotein inhibition and induction in vitro (English)

1 reference

22 September 2017

4

David J Greenblatt

1 reference

22 September 2017

3

Lisa L von Moltke

1 reference

22 September 2017

1

Michael D Perloff

1 reference

22 September 2017

2

Elke Störmer

1 reference

22 September 2017

language of work or name

1 reference

1 August 2003

1 reference

22 September 2017

published in

Pharmaceutical Research

1 reference

22 September 2017

volume

20

1 reference

22 September 2017

issue

8

1 reference

22 September 2017

page(s)

1177-1183

1 reference

Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.

22 September 2017

cites work

1 reference

12 December 2020

Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.

1 reference

12 December 2020

Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein

1 reference

12 December 2020

Multidrug-resistance phenotype in Chinese hamster ovary cells

1 reference

12 December 2020

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1 reference

12 December 2020

P-glycoprotein interactions of nefazodone and trazodone in cell culture

1 reference

12 December 2020

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1 reference

12 December 2020

Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16

1 reference

12 December 2020

Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line

1 reference

12 December 2020

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

1 reference

12 December 2020

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4

1 reference

12 December 2020

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

12 December 2020

Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents

1 reference

12 December 2020

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

12 December 2020

In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein

1 reference

12 December 2020

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction

1 reference

12 December 2020

Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture

1 reference

12 December 2020

The barrier function of CYP3A4 and P-glycoprotein in the small bowel

1 reference

12 December 2020

Caco-2 monolayers in experimental and theoretical predictions of drug transport

1 reference

12 December 2020

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies

1 reference

12 December 2020

Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure

1 reference

12 December 2020

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

1 reference

12 December 2020

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1025092829696

1 reference

22 September 2017

1 reference